TiGenix And Lonza Group Ltd. Sign Agreement For The Manufacture Of Stem Cell-Based Treatment Of Complex Perianal Fistulas In Crohn's Disease TiGenix's Cx601 product is currently in Phase 3 in Europe for the treatment of complex perianal fistulas in Crohn's disease Lonza to manufacture Cx601 product for TiGenix's Phase 3 trial in the US at Lonza's Walkersville, Maryland facility BASEL, Switzerland, and LEUVEN, Belgium, Feb. 12, 2015 -- Lonza, a global leader in biological and cell therapy manufacturing and TiGenix, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today an agreement for the supply of TiGenix's eASC product, Cx601.
http://ift.tt/1J2eF6H
http://ift.tt/1J2eF6H
No comments:
Post a Comment